Qualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville for RAS Interaction Inhibitor Drug Candidates
- Wednesday, July 22, 2020, 7:15
- PR Newswire
- Add a comment
CARLSBAD, Calif. , July 22, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today the signing of an exclusive worldwide license agreement with the University of Louisville (UofL) for the intellectual property covering the “RAS-F” family…
About the Author
admin has written 21717 stories on this site.